APA

Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Bréban M., Pallot-Prades B., Pouplin S., Sacchi A., Chichemanian R. M., Bretagne S., Emilie D., Lemann M., Lortholary O., Lorthololary O. & Mariette X. (20090914). Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. : Arthritis and rheumatism.

Chicago

Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian R M, Bretagne S, Emilie D, Lemann M, Lortholary O, Lorthololary O and Mariette X. 20090914. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. : Arthritis and rheumatism.

Harvard

Tubach F., Salmon D., Ravaud P., Allanore Y., Goupille P., Bréban M., Pallot-Prades B., Pouplin S., Sacchi A., Chichemanian R. M., Bretagne S., Emilie D., Lemann M., Lortholary O., Lorthololary O. and Mariette X. (20090914). Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. : Arthritis and rheumatism.

MLA

Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian R M, Bretagne S, Emilie D, Lemann M, Lortholary O, Lorthololary O and Mariette X. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. : Arthritis and rheumatism. 20090914.